Intec Pharma

The company's business model revolved around leveraging its Accordion Pill platform to improve the efficacy and safety of existing and developing drugs. This technology was designed as an oral drug delivery system with efficient gastric retention and a specific release mechanism. The Accordion Pill consists of biodegradable polymeric films folded into an accordion shape within a standard capsule. Once in the stomach, the capsule dissolves, allowing the folded films to unfold and remain in the stomach for up to twelve hours, continuously releasing the active drug in the upper gastrointestinal tract for better absorption. This aimed to provide more stable drug plasma levels, a particular challenge for medications that require frequent dosing. Beyond its lead Parkinson's candidate, Intec's pipeline included AP-cannabinoids for pain management. The company's strategy also involved collaborations, such as a partnership with LTS to manufacture the AP-CD/LD for its clinical trials and a feasibility agreement with Novartis for a custom-designed Accordion Pill.

Following the disappointing results of the Phase 3 trial, Intec Pharma shifted its corporate direction. In March 2021, the company announced a definitive merger agreement with Decoy Biosystems, a preclinical-stage biotechnology firm focused on immunotherapy. The transaction was completed in August 2021, resulting in the formation of Indaptus Therapeutics, Inc. This reverse merger marked a strategic pivot from drug delivery to immuno-oncology, with the new entity advancing Decoy's platform for treating various tumors and chronic viral infections. As part of the merger conditions, Intec effected a 1-for-4 reverse share split, and the combined company began trading on Nasdaq under the ticker symbol "INDP". The original Intec Pharma shareholders retained approximately 34.4% of the newly formed company.